

Cell Research Corporation announces new senior advisors

28 August 2018 | News

CellResearch identified the broad applicability of cord lining mesenchymal and epithelial stem cells as potential treatments for an extensive number of indications including Haemophilia A, myocardial infarction and Parkinson's disease.



Singapore - Singapore based biotechnology company and leader in cord lining stem cells, CellResearch Corporation announced the appointments of Abbas Hussain and Richard Davies as Senior Advisors to CellResearch's Board, effective immediately.

CellResearch identified the broad applicability of cord lining mesenchymal and epithelial stem cells as potential treatments for an extensive number of indications including Haemophilia A, myocardial infarction and Parkinson's disease.

Using this technology, the Company has also successfully brought to market Colecim Professional, a cosmetic product for skin rejuvenation.

Commenting on the appointments, Gavin Tan, Chief Executive Officer of CellResearch Corporation, said: "Abbas and Richard bring a wealth of global, senior experience in the healthcare industry and I am delighted to have welcomed them to our growing team. Their appointments represent an important step for CellResearch as we continue to build our capabilities in development and commercial excellence."

Abbas Hussain has served the Advisory Board of CellResearch Corporation since August 2017, following a successful career in pharmaceutical leadership.

Abbas Hussain is Senior Advisor at C-Bridge Capital as well as Non-Executive Director of Immunocore Limited, Vigor Medical Systems, Inc. and CSL Limited.

Focusing on the company's wholly-owned cellular therapeutics subsidiary, Richard Davies will offer his guidance and expertise on the commercialisation of CorLiCyte, an umbilical cord lining stem cell cellular therapeutic, in his role as Senior Advisor. The unique platform is based on cord lining mesenchymal stem cells and is currently being developed for the topical

treatment of chronic wounds and ulcers reducing the need for skin grafts. The Company has established robust IP protection for CorLiCyte and reported positive results from a number of studies.